{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:41Z","timestamp":1782100181033,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Farma SpA, Milan, Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00553-x","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:46:04Z","timestamp":1776707164000},"page":"241-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient\u2011Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At\u2011Home Self\u2011Administered Subcutaneous Ofatumumab Versus Other High\u2011Efficacy Therapies"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-2759","authenticated-orcid":false,"given":"Francesco","family":"Pastore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Domenicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"DellOro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977.","journal-title":"Lancet Reg Health Eur"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","volume":"37","author":"S Krieger","year":"2024","unstructured":"Krieger S, Cook K, Hersh CM. Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold. Curr Opin Neurol. 2024;37:189\u2013201. https:\/\/doi.org\/10.1097\/WCO.0000000000001262.","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"553_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45454","volume":"15","author":"I Etta","year":"2023","unstructured":"Etta I, Elballushi R, Kolesnyk V, Sia KP, Rehman S, Arif S, et al. Comparison of pharmacological therapies in relapse rates in patients with relapsing-remitting multiple sclerosis. Cureus. 2023;15(9):e45454. https:\/\/doi.org\/10.7759\/cureus.45454.","journal-title":"Cureus"},{"key":"553_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","volume":"13","author":"JH Yang","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926. https:\/\/doi.org\/10.3389\/fneur.2022.824926.","journal-title":"Front Neurol"},{"key":"553_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13293-9","volume":"272","author":"M Filippi","year":"2025","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus. J Neurol. 2025;272:565. https:\/\/doi.org\/10.1007\/s00415-025-13293-9.","journal-title":"J Neurol"},{"key":"553_CR6","unstructured":"European Medicines Agency. Tysabri: summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf. [Accessed 14 Apr 2026]."},{"key":"553_CR7","unstructured":"European Medicines Agency. Lemtrada: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf. Accessed 14 Apr 2026."},{"key":"553_CR8","unstructured":"European Medicines Agency. Ocrevus: summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Accessed 14 Apr 2026."},{"key":"553_CR9","unstructured":"European Medicines Agency. Kesimpta: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed 14 Apr 2026."},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264:2351\u201374. https:\/\/doi.org\/10.1007\/s00415-017-8594-9.","journal-title":"J Neurol"},{"key":"553_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1063904","volume":"13","author":"DT Ubbink","year":"2022","unstructured":"Ubbink DT, Damman OC, De Jong BA. Shared decision-making in patients with multiple sclerosis. Front Neurol. 2022;13:1063904. https:\/\/doi.org\/10.3389\/fneur.2022.1063904.","journal-title":"Front Neurol"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/WCO.0000000000000324","volume":"29","author":"D Golan","year":"2016","unstructured":"Golan D, Staun-Ram E, Miller A. Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific. Curr Opin Neurol. 2016;29:354\u201361. https:\/\/doi.org\/10.1097\/WCO.0000000000000324.","journal-title":"Curr Opin Neurol"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","volume":"269","author":"F Washington","year":"2022","unstructured":"Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269:1861\u201372. https:\/\/doi.org\/10.1007\/s00415-021-10850-w.","journal-title":"J Neurol"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s40120-024-00654-1","volume":"13","author":"BA Singer","year":"2024","unstructured":"Singer BA, Morgan D, Stamm JA, Williams AA. Patient and physician perspectives of treatment burden in multiple sclerosis. Neurol Ther. 2024;13:1507\u201325. https:\/\/doi.org\/10.1007\/s40120-024-00654-1.","journal-title":"Neurol Ther"},{"key":"553_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57116-9","volume":"14","author":"EM Khedr","year":"2024","unstructured":"Khedr EM, Mahmoud DM, Hussein HB, Malky IEL, Mostafa SS, Gamea A. Treatment satisfaction with disease-modifying therapy is the only predictor of adherence among multiple sclerosis patients from Upper Egypt. Sci Rep. 2024;14:7027. https:\/\/doi.org\/10.1038\/s41598-024-57116-9.","journal-title":"Sci Rep"},{"key":"553_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042203","volume":"19","author":"A Ko\u0142tuniuk","year":"2022","unstructured":"Ko\u0142tuniuk A, Chojdak-\u0141ukasiewicz J. Adherence to therapy in patients with multiple sclerosis: review. Int J Environ Res Public Health. 2022;19:2203. https:\/\/doi.org\/10.3390\/ijerph19042203.","journal-title":"Int J Environ Res Public Health"},{"key":"553_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12725-2","volume":"272","author":"C Gasperini","year":"2024","unstructured":"Gasperini C, Battaglia MA, Balzani F, Chiarini E, Pani M, Pasqualetti P, et al. Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals. J Neurol. 2024;272:27. https:\/\/doi.org\/10.1007\/s00415-024-12725-2.","journal-title":"J Neurol"},{"key":"553_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1407257","volume":"15","author":"P Zaratin","year":"2024","unstructured":"Zaratin P, Samadzadeh S, Sefero\u011flu M, Ricigliano V, Dos Santos Silva J, Tunc A, et al. The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event. Front Neurol. 2024;15:1407257. https:\/\/doi.org\/10.3389\/fneur.2024.1407257.","journal-title":"Front Neurol"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/13524585231164295","volume":"29","author":"E Rodriguez Llorian","year":"2023","unstructured":"Rodriguez Llorian E, Zhang W, Khakban A, Michaux K, Patten S, Traboulsee A, et al. Employment status, productivity loss, and associated factors among people with multiple sclerosis. Mult Scler. 2023;29:866\u201374. https:\/\/doi.org\/10.1177\/13524585231164295.","journal-title":"Mult Scler"},{"key":"553_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0375-4","volume":"15","author":"K van der Hiele","year":"2015","unstructured":"van der Hiele K, van Gorp DAM, Heerings MAP, van Lieshout I, Jongen PJ, Reneman MF, et al. The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting multiple sclerosis. BMC Neurol. 2015;15:134. https:\/\/doi.org\/10.1186\/s12883-015-0375-4.","journal-title":"BMC Neurol"},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.23736\/S1973-9087.20.05914-6","volume":"56","author":"M P\u00e9rez De Heredia-Torres","year":"2020","unstructured":"P\u00e9rez De Heredia-Torres M, Huertas-Hoyas E, S\u00e1nchez-Camarero C, M\u00e1ximo-Bocanegra N, Alegre-Ayala J, S\u00e1nchez-Herrera-Baeza P, et al. Occupational performance in multiple sclerosis and its relationship with quality of life and fatigue. Eur J Phys Rehabil Med. 2020;56:148\u201354. https:\/\/doi.org\/10.23736\/S1973-9087.20.05914-6.","journal-title":"Eur J Phys Rehabil Med"},{"key":"553_CR22","unstructured":"AISM (Italian Multiple Sclerosis Association). Barometer of multiple sclerosis and related diseases 2025. 2025. https:\/\/agenda.aism.it\/2024\/download\/Barometro_della_Sclerosi_Multipla_2025.pdf. Accessed 21 Aug 2025."},{"key":"553_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265297","volume":"18","author":"S Benini","year":"2023","unstructured":"Benini S, Pellegrini E, Descovich C, Lugaresi A. Burden and resources in caregivers of people with multiple sclerosis: a qualitative study. PLoS ONE. 2023;18:e0265297. https:\/\/doi.org\/10.1371\/journal.pone.0265297.","journal-title":"PLoS ONE"},{"key":"553_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.7224\/1537-2073.2017-070","volume":"20","author":"A Ben-Zacharia","year":"2018","unstructured":"Ben-Zacharia A, Adamson M, Boyd A, Hardeman P, Smrtka J, Walker B, et al. Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. Int J MS Care. 2018;20:287\u201397. https:\/\/doi.org\/10.7224\/1537-2073.2017-070.","journal-title":"Int J MS Care"},{"key":"553_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03190-x","volume":"23","author":"D Rau","year":"2023","unstructured":"Rau D, Eichau S, Borriello G, Cerqueira J, Wagner C. Assessment of the treating physicians\u2019 first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe. BMC Neurol. 2023;23:147. https:\/\/doi.org\/10.1186\/s12883-023-03190-x.","journal-title":"BMC Neurol"},{"key":"553_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03100-1","volume":"23","author":"AP Ross","year":"2023","unstructured":"Ross AP, Besser C, Naval S, Stoneman D, Gaunt H, Barker N. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey. BMC Neurol. 2023;23:85. https:\/\/doi.org\/10.1186\/s12883-023-03100-1.","journal-title":"BMC Neurol"},{"key":"553_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-04007-1","volume":"25","author":"AP Ross","year":"2025","unstructured":"Ross AP, Nicholas J, Tai M-H, Yeung S, Shaikh NF, Chen H, et al. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis. BMC Neurol. 2025;25:28. https:\/\/doi.org\/10.1186\/s12883-024-04007-1.","journal-title":"BMC Neurol"},{"key":"553_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;15:811\u201334. https:\/\/doi.org\/10.2147\/PPA.S303279.","journal-title":"Patient Prefer Adher"},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s41669-023-00394-2","volume":"7","author":"AM Alonso Torres","year":"2023","unstructured":"Alonso Torres AM, Ar\u00e9valo Bernab\u00e9 AG, Becerril R\u00edos N, Hell\u00edn Gil MF, Mart\u00ednez Sesmero JM, Meca Lallana V, et al. Cost-analysis of subcutaneous vs intravenous administration of natalizumab based on patient care pathway in multiple sclerosis in Spain. PharmacoEcon Open. 2023;7:431\u201341. https:\/\/doi.org\/10.1007\/s41669-023-00394-2.","journal-title":"PharmacoEcon Open"},{"key":"553_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202406604","volume":"36","author":"G Jacquot","year":"2024","unstructured":"Jacquot G, Lopez Navarro P, Grange C, Boudali L, Harlepp S, Pivot X, et al. Landscape of subcutaneous administration strategies for monoclonal antibodies in oncology. Adv Mater. 2024;36:e2406604. https:\/\/doi.org\/10.1002\/adma.202406604.","journal-title":"Adv Mater"},{"key":"553_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32070392","volume":"32","author":"P Mirzadeh","year":"2025","unstructured":"Mirzadeh P, Pituskin E, Au I, Sneath S, Buick CJ. Cancer immunotherapy: the role of nursing in patient education, assessment, monitoring, and support. Curr Oncol. 2025;32:392. https:\/\/doi.org\/10.3390\/curroncol32070392.","journal-title":"Curr Oncol"},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/pon.5750","volume":"30","author":"EA Noteboom","year":"2021","unstructured":"Noteboom EA, May AM, Van Der Wall E, De Wit NJ, Helsper CW. Patients\u2019 preferred and perceived level of involvement in decision making for cancer treatment: a systematic review. Psychooncology. 2021;30:1663\u201379. https:\/\/doi.org\/10.1002\/pon.5750.","journal-title":"Psychooncology"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00553-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:22Z","timestamp":1782098362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00553-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00553-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"6 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Pastore received speaker honoraria from Biogen, Merck, Neuraxpharm, Novartis, Roche, and Sandoz. Emanuela Domenicone has no conflicts of interest that are directly relevant to the content of this article. Patrizia DellOro and Charlotte Lefort are employed by Novartis Farma SpA, Milan, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the current European General Data Protection Regulation (Regulation EU 2016\/679). All participants received detailed information about the objectives, procedures, voluntary nature, and data protection measures of the study, and provided informed consent prior to questionnaire completion. Submission to an ethics committee was not required, according to the most recent provisions of the Italian Medicines Agency (AIFA, 2024) regarding non-interventional studies that do not involve the collection of biological samples or clinical interventions. All data have been collected according to the 2025 European Pharmaceutical Market Research Association Code of Conduct (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Before providing informed consent to participate and accessing the questionnaire, participants were informed that the survey was conducted for research purposes with the aim of better understanding treatment satisfaction among people with relapsing-remitting multiple sclerosis and that the data collected for the study could be used for scientific dissemination in aggregated form. Participants were informed that they could ask their treating healthcare professional or contact the study team if they had any questions regarding the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FP: conceptualization, methodology, investigation, data curation, formal analysis, writing (original draft), writing (review and editing). ED: investigation, project administration, writing (review and editing. PDO: conceptualization, writing (review and editing). CL: conceptualization, writing (review and editing). All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}